Amyloid-β and Alzheimer’s disease type pathology differentially affects the calcium signalling toolkit in astrocytes from different brain regions

AA Grolla1,2, JA Sim3, D Lim1, JJ Rodriguez2,4, AA Genazzani1 and A Verkhratsky*2,3,4

The entorhinal–hippocampal circuit is severely affected in Alzheimer’s disease (AD). Here, we demonstrate that amyloid-β (Aβ) differentially affects primary cultured astrocytes derived from the entorhinal cortex (EC) and from the hippocampus from non-transgenic controls and 3xTg-AD transgenic mice. Exposure to 100 nM of Aβ resulted in increased expression of the metabotropic glutamate receptor type 5 (mGluR5) and its downstream InsP3 receptor type 1 (InsP3R1) in hippocampal but not in EC astrocytes. Amplitudes of Ca2+ responses to an mGluR5 agonist, DHPG, and to ATP, another metabotropic agonist coupled to InsP3Rs, were significantly increased in Aβ-treated hippocampal but not in EC astrocytes. Previously we demonstrated that senile plaque formation in 3xTg-AD mice triggers astrogliosis in hippocampal but not in EC astrocytes. The different sensitivities of the Ca2+ signalling toolkit of EC versus hippocampal astrocytes to Aβ may account for the lack of astrogliosis in the EC, which in turn can explain the higher vulnerability of this region to AD.

Citation: Cell Death and Disease (2013) 4, e623; doi:10.1038/cddis.2013.145; published online 9 May 2013

Subject Category: Neuroscience

Neuroglia are homeostatic cells of the central nervous system, which are ultimately involved in many (if not all) forms of neuropathology.1, 2 The pathological potential of neuralglial cells was recognized already by Rudolf Virchow, who comprehended that neuroglia ‘is one of the most frequent seats of morbid change’.3 Pathologically remodelled glial cells associated with various types of neurological conditions have been subsequently identified by prominent histopathologists such as Nissl, Frommann and Alzheimer (see Kettenmann and Verkhratsky4 for a historical review). Alzheimer5 made the first descriptions of pathological glia in the context of dementia and identified glial cells as morphological components of senile plaques.

Astrocytes are the principal homeostatic cells of the central nervous system. The role of astroglia in the pathogenesis of Alzheimer’s disease (AD) remains generally unknown although the interest in astroglial remodelling in the course of neurodegeneration has increased substantially during the last decade.1, 6–9 AD is considered to be one of the most prevalent forms of dementia in humans,10 the symptoms of which are manifested by progressive cognitive impairment.11–12 The loss of synapses, in particular, is considered to be the earliest AD-associated cellular pathology responsible for early signs of cognitive failure.13, 14 This loss of synapses may reflect functional downfall of astrocytes that are generally responsible for synaptic maintenance and homeostasis of ionic and neurotransmitters, the latter being critical for synaptic transmission. Indeed, recent data indicated atrophic changes in astroglia at the early (i.e., pre-plaque) stages of AD-like pathology in transgenic model animals, which may account for the deficient synaptic connectivity.9, 15, 16 At the later stages, the emergence of β-amyloid depositions and formation of senile plaques trigger reactive astrogliosis, which mainly occurs in cells directly associated with β-amyloid plaques.15, 16

The spatio-temporal progression of AD is well identified, with the entorhinal cortex (EC) being the very first area to be affected by the pathology.17 Neurons in superficial layers of the EC innervate all hippocampal subregions, including the dentate gyrus (DG), CA3, CA1 and subiculum via the perforant pathway; synaptic connections between mossy fibers of DG and CA3 neurons and Schaffer collaterals from CA3 to CA1 neurons complete the forward hippocampal circuit.18 In AD, a significant loss of neurons in EC layer II...
occurs at the early stages. In AD patients, the EC could be the region from which the pathological process spreads towards other brain regions; this has been initially hypothesized because expression of APP, the precursor of β-amyloid, was higher in EC layer II neurons than in other brain areas. Moreover, APP synthesized by EC neurons is transported via the perforant pathway to presynaptic terminals in DG. A profound reduction in β-amyloid burden was observed in DG, following unilateral severance of the perforant pathway.

Our previous morphological analysis found a remarkable difference in the AD-associated behavior of astrocytes in the EC. In contrast to the hippocampus, where reactive astrocytes were a prominent feature of β-amyloid depositions, in EC astrocytes failed to show any reactivity and were not specifically associated with β-amyloid. In this study, we analyzed Ca²⁺ signalling and the metabotropic Ca²⁺ signalling molecular toolkit in EC and hippocampal astrocytes in vitro in cell cultures. We found that these astroglial populations have distinct reactions to β-amyloid treatment that may account for differences in their reactivity in the pathological context.

**Results**

Astroglial cultures derived from the EC and hippocampus are morphologically different. The morphology of astroglial cells from the EC and hippocampus, when maintained in vitro for the first 3–5 days, was characteristically different. In hippocampal cultures, majority of the cells were large and flat (or star-shaped), whereas in EC cultures many cells were thin and oblong with almost needle-like morphology. Figure 1a shows the differences in morphology between cultured astrocytes derived from the hippocampus and astrocytes derived from the EC. Both types of cells were positive to glial fibrillary acidic protein (GFAP) immunostaining, confirming thus their astroglial nature (Figure 1b). The morphology of EC astrocytes maintained in culture was similar to their appearance in situ (Figure 1c). The quantification of the number of thin and oblong cells shows a significantly higher percentage of this morphological profile in EC cultures (Figures 1a, b and d). The overall morphological features of astrocytes from non-Tg and 3xTg-AD mice did not show any significant differences (Figure 1b).

Of interest, in older cultures, we also observed different proportions of large flat ‘proliferating’ cells and star-shaped ‘reactive’ cells (expressing high levels of GFAP) in hippocampal versus EC cultures, the number of ‘reactive’ astrocytes being substantially higher in the former (the % of star-shaped cells in hippocampal cultures was 21.3 ± 3.07, whereas that in EC cultures was 9.65 ± 2.05, P < 0.05; n = 240 cells from four cultures).

Aβ oligomers differentially affect the expression of mGluR5 and InsP3R1 in astrocytes from EC and hippocampus. Previously we have demonstrated that Aβ-oligomers affect the calcium signalling cascade in astrocytes derived from rat hippocampus, by increasing the expression of metabotropic glutamate receptor type 5 (mGluR5) and its downstream receptor, InsP3 receptor type 1 (InsP3R1), which resulted in an increased amplitude of Ca²⁺ responses to selective mGluR5 agonist, DHPG. Here, we compared the effects of Aβ oligomers on the expression of

---

**Figure 1** Morphological differences between cultured astrocytes derived from EC and hippocampus. (a) Microphotographs show the phase-contrast images of live (non fixed) hippocampal cultured astrocytes (left) and EC cultured astrocytes (right) at 4 days in vitro. (b) Representative images of GFAP-stained hippocampal and EC astrocytes derived from non-Tg control and 3xTg-AD model animals. Left panels represent images of GFAP immunofluorescence of stained cells, whereas right panels show merged images of phase-contrast images (gray) and GFAP/DAPI (green/blue) staining obtained from the same cells and fields of view. (c) In situ images of GFAP-stained hippocampal and EC astrocytes; the cells were GFAP labelled in slices obtained from 6-month-old non-Tg animals. For technical details, see Olabarria et al. and Yeh et al. (d) Quantification of the percentage of thin, long needle-shaped and flat or stellate cells in cultures prepared from hippocampus and the EC; n = 320, from four different cultures **P < 0.01**.
mGluR5 and InsP3R1 in astrocytes derived from the hippocampus and EC of 7-day-old non-Tg and 3xTg-AD mice.

First, we confirmed the presence of these receptors in astrocytes cultured from both the hippocampus and the EC of non-Tg control mice by immunocytochemistry (Figure 2a). Treatment with 100 nM Aβ1-42 induced strong and rapid upregulation of mGluR5 and InsP3R1 expression only in hippocampal astrocytes derived from non-Tg mice. This increase in receptor expression was already present after 48 h (data not shown), and was even more pronounced after 72 h of treatment (Figure 2b, upper panel).

In contrast, Aβ-treatment of astrocytes isolated from the EC of non-Tg mice did not affect the expression of either mGluR5 or InsP3R1 (Figure 2b, lower panel). Further, Aβ-oligomers had no effect on the expression of both receptors in astrocytes isolated from the hippocampus and EC of 3xTg-AD mice, although the basal levels of these proteins were different. In both EC and hippocampal astrocytes obtained from these mice, basal expression of mGluR5 was lower, whereas that of InsP3R1 was higher compared with non-Tg control mice (Figure 2b).

Metabotropic glutamatergic calcium signalling is differentially affected by Aβ in EC and hippocampal astrocytes. The group I mGluR family is composed of two members (mGluR1 and mGluR5). Our previous study revealed that mGluR5 was the sole receptor responsible for DHPG-induced Ca2+ transients in astrocytes. Moreover, mGluR1 is either absent or present at low levels in these cells, as also has been observed by others.

After treating the astrocytes from the EC and hippocampus of non-Tg and 3xTg-AD mice with 100 nM Aβ1-42 oligomers, cells were loaded with the calcium probe Fluo4-AM, and their responses to 100 nM DHPG (15 s) were analyzed. Figures 3a and b show representative traces of DHPG-induced Ca2+ responses in astrocytes derived from the hippocampus and EC of non-Tg and 3xTg-AD mice. Treatment with Aβ significantly increased the amplitude of DHPG-responses in hippocampal astrocytes when compared with control. The same treatment, however, did not modify Ca2+ responses in EC astrocytes derived from the same mice (Figure 3b). The integrals (‘area under the curve’) of [Ca2+]i transient that represent the overall Ca2+ load of stimulated cells were 26.20 ± 5.77 in non-Tg control hippocampal astrocytes versus 46.09 ± 7.41 in non-Tg Aβ-treated hippocampal astrocytes (P < 0.05), and 16.57 ± 5.32 in non-Tg control EC astrocytes versus 14.36 ± 5.35 in non-Tg Aβ-treated EC astrocytes (P = 0.75) (Figure 3c, n = 150 cells from five different cultures for each experimental protocol).

In astrocytes from 3xTg-AD animals, Aβ oligomers did not affect the DHPG-mediated Ca2+ responses, neither in hippocampal nor in EC astrocytes (Figure 3c). The overall amplitudes of DHPG-induced Ca2+ responses in EC astrocytes were lower than in cells from the hippocampus ([Ca2+]i transient integral 28.65 ± 5.76 in 3xTg-AD control hippocampal astrocytes versus 24.51 ± 9.33 in 3xTg-AD Aβ-treated hippocampal astrocytes (P = 0.66); and 11.13 ± 6.88 in 3xTg-AD control EC astrocytes versus 18.70 ± 8.25 in 3xTg-AD-treated Aβ EC astrocytes (P = 0.44), n = 150 cells from five cultures).
Purinergic calcium signalling is differentially affected by Aβ in EC and hippocampal astrocytes. Ca²⁺ responses to ATP stimulation were examined in astrocytes from the EC and hippocampus subjected to 72 h of incubation with Aβ1-42 oligomers. Treatment with Aβ resulted in an increase of ATP-induced Ca²⁺ signals only in astrocytes isolated from the hippocampus of non-Tg mice compared to control cells (Figure 4). Mean values for integrals of [Ca²⁺]i, transients were 15.30 ± 1.50 in non-Tg control hippocampal astrocytes versus 29.11 ± 2.12 in non-Tg Aβ-treated hippocampal astrocytes (P < 0.01); and 9.64 ± 0.36 in non-Tg control EC astrocytes versus 19.60 ± 6.56 in non-Tg Aβ-treated EC astrocytes (P = 0.37); n = 150 cells from five cultures).

3xTg-AD hippocampal astrocytes showed basal calcium deregulation when stimulated with ATP. Treatment with Aβ did not affect ATP-induced Ca²⁺ responses in astrocytes from 3xTg-AD mice from both the EC and hippocampus (Figure 4; integrals of [Ca²⁺]i, transients were 29.15 ± 2.05 in 3xTg-AD control hippocampal astrocytes versus 32.56 ± 3.40 in 3xTg-AD Aβ-treated hippocampal astrocytes (P = 0.34); and 15.75 ± 6.57 in 3xTg-AD control EC astrocytes versus 30.79 ± 11.98 in 3xTg-AD Aβ-treated EC astrocytes (P = 0.36); n = 120 cells from four different cultures). However, in hippocampal astrocytes derived from 3xTg-AD mice, the amplitudes of ATP-calcium responses in control cells were significantly higher compared with that measured in astrocytes derived from non-Tg mice (Figure 4c, integrals of [Ca²⁺]i, transients being 15.30 ± 1.50 versus 29.15 ± 2.05, P < 0.01). In that, the amplitudes of ATP-mediated Ca²⁺ responses in hippocampal astrocytes derived from 3xTg-AD mice ([Ca²⁺]i, 29.15 ± 2.05) were comparable to the amplitudes of ATP-mediated Ca²⁺ responses in Aβ-treated hippocampal astrocytes derived from non-Tg mice ([Ca²⁺]i, 29.11 ± 2.12). In contrast, there was little difference between the amplitudes of ATP-mediated Ca²⁺ responses in astrocytes from the EC of non-Tg mice and 3xTg-AD mice (Figure 4c, integrals of [Ca²⁺]i, transients were 9.64 ± 3.68 versus 15.75 ± 6.57, P = 0.13).

Discussion

In this study, we have investigated the effect of Aβ oligomers on calcium signalling cascades in astrocytes derived from two brain regions predicted to be principally involved in AD pathology, namely, the hippocampus and EC. The key findings presented in this paper are: (1) astrocytes derived from the hippocampus and EC retain their morphological phenotype in vitro for several days after isolation; (2) astrocytes from these two different regions have distinct Ca²⁺ signalling toolkits that are differentially affected by Aβ-oligomers. Of particular interest are: (i) treatment of healthy astrocytes with Aβ increased the expression of mGluR5 and InsP3R1 only in hippocampal astrocytes; (ii) in agreement with this, Aβ treatment potentiated Ca²⁺ responses mediated through mGluR5/InsP3Rs cascade only in hippocampal and not in EC astrocytes; and (iii) treatment with Aβ did not affect Ca²⁺ signalling in astrocytes isolated from the transgenic animal model of AD.

Our previous results showed a concomitant occurrence of astroglial atrophy, as a generalized process, and astrogliosis of the astrocytes surrounding senile plaques in hippocampus.
of 3xTg-AD mice. Subsequently, we found that although the astroglial atrophy persisted in the EC and in the prefrontal cortex, the astrogliotic reaction in the EC was absent. We failed to observe any signs of hypertrophy in EC astrocytes in both non-Tg and 3xTg-AD animals at all ages up to 18 months. The present study was designed to determine functional differences between astrocytes from different brain areas.

First, we confirmed in primary cell culture our previous in situ results, that astrocytes even after isolation from the brain retain their morphological idiosyncrasies for 3–5 days in vitro: astrocytes from the EC remained characteristically needle-shaped, whereas hippocampal astrocytes had more of a star-like appearance. Furthermore, we observed that overall percentage of stellate astroglial cells was higher in hippocampal cultures, which may be indicative of their higher intrinsic reactivity.

Different hypotheses are recognized for AD pathology, because of its multifactorial trait. One of them is the ‘amyloid hypothesis’, in which the main cause of AD is the deposition of amyloid-β plaques (senile plaques) that disrupted the normal activity of neurons in the brain. Another hypothesis assumed the pathological role of abnormal Ca^{2+} homeostasis; this ‘calcium hypothesis’ of neurodegeneration postulates that Aβ affects calcium homeostasis/neurodegeneration and is considered to be of fundamental importance for cellular pathology in AD. The key pathway of astroglial Ca^{2+} signalling is represented by a metabotropic route that comprises seven transmembrane domain G protein-coupled receptors (of which glutamate and purinoceptors are the most abundant in glia), phospholipase C and InsP_{3}R located at the endomembrane.

We established that treatment with pathologically relevant (100 nM) concentrations of Aβ affects the metabotropic Ca^{2+} signalling toolkit in EC and hippocampal astrocytes in a very different way. Exposure to Aβ increased the expression of both mGluR5 and InsP_{3}R1 in hippocampal astrocytes. This increase in expression of Ca^{2+} signalling molecules resulted in an increase in the amplitude of [Ca^{2+}]_{i} transients following stimulation with mGluR5 agonist DHPG or ATP. In contrast, treatment with Aβ neither affected expression of metabotropic Ca^{2+} signalling toolkit, nor modified the parameters of DHPG and ATP-induced Ca^{2+} transients in EC astrocytes.

For these reasons, the present study was focused on calcium signalling pathways, which are critically involved in astroglial functions in health and disease. Disruption of Ca^{2+} homeostasis is implicated in many forms of neuro-pathology, and in particular Ca^{2+} deregulation is considered to be of fundamental importance for cellular pathology in AD. The key pathway of astroglial Ca^{2+} signalling is represented by a metabotropic route that comprises seven transmembrane domain G protein-coupled receptors (of which glutamate and purinoceptors are the most abundant in glia), phospholipase C and InsP_{3}R located at the endomembrane.

We established that treatment with pathologically relevant (100 nM) concentrations of Aβ affects the metabotropic Ca^{2+} signalling toolkit in EC and hippocampal astrocytes in a very different way. Exposure to Aβ increased the expression of both mGluR5 and InsP_{3}R1 in hippocampal astrocytes. This increase in expression of Ca^{2+} signalling molecules resulted in an increase in the amplitude of [Ca^{2+}]_{i} transients following stimulation with mGluR5 agonist DHPG or ATP. In contrast, treatment with Aβ neither affected expression of metabotropic Ca^{2+} signalling toolkit, nor modified the parameters of DHPG and ATP-induced Ca^{2+} transients in EC astrocytes.

Figure 4 Effect of Aβ treatment on metabotropic purinergic Ca^{2+} signalling in EC and hippocampal astrocytes from non-Tg and 3xTg-AD mice. (a and b) Representative traces of ATP-induced Ca^{2+} responses in hippocampus and EC in control cells and in Aβ-treated cells derived from non-Tg mice, and control and Aβ-treated cells derived from 3xTg-AD mice (n = 30 cells for each experimental protocol). The cells were exposed to 100 nM of Aβ for 72 h and then loaded with Fluo4-AM and stimulated with 100 μM ATP for 15 s. (c) Mean values for integrals of [Ca^{2+}]_{i} transients induced by ATP stimulation (n = 150 cells from five different cultures for each experimental protocol).
mGlur5 and InsP3R1 were substantially modified in pathologically remodelled astrocytes compared with non-transgenic controls. Similarly, stimulation of astrocytes with agonists triggered [Ca\(^{2+}\)]\(_i\) transients with higher amplitudes compared with cells from healthy wild-type controls. We can therefore suggest that expression of AD-related mutant genes deregulates Ca\(^{2+}\) homeostasis and signalling in astroglia.

In conclusion, we have shown that astrocytes from different brain regions display different patterns of response to exogenous A\(_\beta\). This transpires to different responses of the Ca\(^{2+}\)\(_i\) signalling toolkit to a pathological context and may account for the different reactivities of astroglia observed in the whole tissue to the progression of AD. We may therefore speculate that the distinct responsiveness of Ca\(^{2+}\)\(_i\) signalling machinery in EC astrocytes can be linked to their inability to mount astrogliotic response to \(\beta\)-amyloid deposition, which in turn can underlie the higher vulnerability of EC to AD-like pathology. This far-reaching speculation naturally requires future experiments and, above all, analysis of [Ca\(^{2+}\)]\(_i\) signalling in astrocytes from different brain regions in situ and in vivo.

Materials and Methods

All animal procedures were carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986 under the license from Home Office. All efforts were made to reduce the number of animals by following the 3Rs.

Animal models. Experiments were performed on 3Tg-AD mice, introduced by Frank LaFerla and Salvatore Oddo in 2003.\(^{42}\) These mice were developed on the mixed 129/C57BL6 background and harbor APP\(_\text{sw}\), PS1M146V and TauF301L mutations. The 3Tg-AD animals show major hallmarks of AD represented by senile plaques and neurofibrillary tangles. The non-Tg (non-transgenic) control mice were from the same strain and the same genetic background. All 3Tg-AD and non-Tg littermates were from homozygous breeders.

Primary astrocyte cultures and A\(_\beta\) treatment. The EC and hippocampus were dissected from the brains of 7-day-old non-Tg and 3Tg-AD mice. Purified glial cell cultures were prepared as described previously.\(^{46}\) Isolated astrocytes were seeded in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/l D-glucose (Gibco 11960-044; Life Sciences Ltd, Paisley, UK), supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 10 U/ml penicillin and 100 \(\mu\)g/ml streptomycin (Sigma, Dorset, UK). The cells were grown until confluence (2–4 days) and then were plated on coverslips coated with 0.1 mg/ml poly-L-lysine. The purity of cultures was assessed by immunostaining with anti-MAP2 (neuronal marker) and anti-GFAP (glial marker) and anti-Iba1 (microglial marker).

Both neurons and microglia accounted for <0.5% of all cells. Astrocytes were treated after 4 days in vitro (DIV) with 100 nM of A\(_\beta_{1–42}\) oligomers for 48 or 72 h, and then analyzed by calcium imaging or western blot. As negative controls, we used an inactive form of amyloid protein A\(_\beta_{1–42}\) (100 nM) and vehicle (physiological saline); neither had any effect on expression of components of the Ca\(^{2+}\)\(_i\) signalling pathway and tools of Ca\(^{2+}\)\(_i\) signals.

Preparation of A\(_\beta_{1–42}\) oligomers. A\(_\beta_{1–42}\) peptide was oligomerized as described previously,\(^{46}\) with some modifications. Briefly, 1 mg of A\(_\beta\) was diluted in 1 ml of 1,1,1,3,3,3-hexa-flouro-2-propanol (HFIP, 52512 Fluka, Sigma) and incubated for 1 h at 37 °C. Then, HFIP was lyophilized by using a SpeedVac concentrator (Thermo Fisher Scientific, Loughborough, UK). The A\(_\beta\) pellet was subsequently dissolved in 5 mM DMSO and then diluted to 100 \(\mu\)M in ice-cold cell phosphate buffer. The solution was incubated overnight at 4 °C, which favoured oligomerization. Aliquots were stored at −20 °C. The presence of oligomers was verified by loading the A\(_\beta\) preparation in a native gel stained with Coomassie.

Immunocytochemistry. Cultured astrocytes were fixed in 4% formaldehyde in PBS for 7 min at room temperature. Subsequently, primary and secondary antibodies were applied in GDB buffer, as described previously.\(^{46}\) Fluorescence images were acquired using a Zeiss Axiosvert 25 microscope equipped with a Zeiss AxioCam HRc camera (Carl Zeiss Ltd, Welwyn Garden City, UK). Green fluorescence was detected at 515–565 nm following excitation at 450–490 nm; red fluorescence was detected at 590 nm following excitation at 546 nm; blue fluorescence was detected at 397 nm following excitation at 365 nm. Phase-contrast images were obtained with the same microscopy setup.

Western blotting analysis. 1.0 × 10\(^6\) cells were scraped and lysed in Lysis buffer composed of 20 mM HEPES, 100 mM NaCl, 5 mM EDTA, 1% NP-40 + Halt Protease & Phosphatase Inhibitor Cocktail (Thermo Scientific, Fisher Scientific, Loughborough, UK). Protein quantification was performed with Bio-Rad Protein Assay (Bio-Rad, Hemel Hempstead, UK) and 50 \(\mu\)g of proteins was resolved on 5–10% gradient SDS-PAGE. Densitometric analysis was performed with Quantity One program (Bio-Rad).

Calcium imaging. Cells were loaded with 3 \(\mu\)M of Fluo4-AM in Krebs-Ringer modified buffer (KRB) (136 mM NaCl, 20 mM HEPES, 5.5 mM glucose, 1.2 mM KH\(_2\)PO\(_4\), 1.2 mM MgSO\(_4\), 5 mM NaHCO\(_3\), 1.8 mM KCl, 2 mM CaCl\(_2\) pH 7.4) supplemented with 0.01% pluronic acid for 30 min at 37 °C. After de-esterification (30 min at 37 °C), the coverslips were placed in a perfusing chamber, mounted on the stage of an inverted confocal microscope (Nikon Eclipse TE300: Nikon Instruments Europe BV, Amstelveen, Netherlands). Cells were superfused with KRB at 8 ml/min and maintained at 37 °C. Cells were excited at 488 nm excitation laser (emitted light filtered at 515 ± 30 nm) and viewed using a ×20 dry objective (NA 0.5). Fluorescent images were taken from the middle of the cell volume, and time series acquisition was controlled with EZ-C1 Nikon software. Drugs were applied by superfusion. To quantify the differences in the peaks of Ca\(^{2+}\) transients, the values were normalized using the formula (F\(_o\) – F\(_i\))/F\(_o\) (where F\(_o\) is the value of fluorescence recorded during the stimulation and F\(_i\) is the basal value of fluorescence recorded).

Reagents. Amyloid \(\beta\) protein (1–42) hydrochloride salt (H-6466) was purchased from Bachem AG (Budendorf, Switzerland), Rabbit polyclonal antibody anti-InsP\(_3\)R1 (AB5882) and rabbit polyclonal antibody anti-mGlur5 (AB5675) were from Millipore (Wallford, UK); goat antibody anti-GFAP (SAB250462) and adenosine triphosphate (ATP) were from Sigma; anti-\(\beta\)-actin HRP-conjugated antibody from Santa Cruz Biotechnology (Heidelberg, Germany), Sc-47778 HRP; peroxidase-conjugated secondary antibodies were from GE Healthcare ( Bucks, UK); (S)-3,5-dihydroxyphenylglycine (DHPG) was from Tocris Bioscience (Bristol, UK); Fluo-4-AM calcium probe (F14201) and Pluronic F-127 (P3000MP) were from Invitrogen (Paisley, UK).

Statistical analysis. For multiple comparisons ANOVA analysis was used with Prism Graph Pad software. Between two groups Student’s t-test or one-sample t-test was used. Differences were considered significant at P < 0.05.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. We thank Sarah Lawton for technical help. The work has been supported by grant 2008–2319 from Fondazione Cariplo, by The Welcome Trust and by The Alzheimer’s Research Trust (UK). Support from the Spanish Government, Plan Nacional de I+D+i 2008-2011 and ISCIII-Subdirección General de Evaluación y Fomento de la Investigación (PI010/02738) co-financed by FEDER to JJR and AV as well as the Government of the Basque Country (AE-2010-1-28, AEGV10/16, GV-2011111020) to JJR are gratefully acknowledged.

1. Verkhratsky A, Schöniew MV, Messing A, deLanerolle NC, Rempe D, Rodriguez JJ et al. Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro 2012; 4: e00082.
2. Giaume C, Kirchhoff F, Matute C, Reichenbach A, Verkhratsky A. Glia: the fulcrum of brain diseases. ASN Neuro 2012; 4: 400–8.
3. Vichrov R. Die Celluläopathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. Zwarzig Vorlesungen gehalten während der Monate Februar, März und April 1858 in den pathologischen Institut zu Berlin., 1st edn. August Hirschwald: Berlin, 1858.
4. Ketenmann H, Verkhratsky A. Neuroglia: the 150 years after. Trends Neurosci 2008; 31: 653–659.

5. Alzheimer A. Beiträge zur Kenntnis der pathologischen Neuroglia und ihrer Beziehungen zu den Abbauprozessen im Nervengewebe. In: Nissl F, Alzheimer A (eds) Histologische und histo pathologische Arbeiten über die Großhirrinde mit besonderer Berücksichtigung der pathologischen Anatomie der Geisteskrankheiten vol. 1–3 (Gustav Fischer: Jena, 1910.; pp 401–562.

6. Heneka MT, Rodriguez JJ, Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev 2010; 63: 169–211.

7. Messing A, Bremer M, Feany MB, Niedergaard M, Goldman JE. Alexander disease. J Neurosci 2012; 32: 5017–5023.

8. Rossi D, Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull 2009; 80: 224–232.

9. Rodriguez JJ, Olabarria M, Chvatáal A, Verkhratsky A. Astroglia in dementia and Alzheimer's disease. Cell Death Differ 2009; 16: 378–385.

10. Braak E, Griffig K, Arai K, Boh J, Bratzke H, Braak H. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 1999; 249(Suppl 3): 14–22.

11. Patop JJ, Mucke L. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010; 13: 810–818.

12. Sheng M, Sabatini BL, Sudhof TC. Synapses and Alzheimer's disease. Cold Spring Harbor Perspect Biol 2012; 4: a005777.

13. Mucke L, Sabatini BL, Sudhof TC. Synapses and Alzheimer's disease. J Biol Chem 2013; 288: 453–456.

14. Terry RD. Cell death or synaptic loss in Alzheimer disease.

15. Mucke L, Selkoe DJ. Neurotoxicity of amyloid β.

16. Sheng M, Sabatini BL, Sudhof TC. Synapses and Alzheimer's disease. Nat Rev Neurosci 2012; 13: 133–149.

17. Lipton PA, Eichenbaum H. Complementary roles of hippocampus and medial entorhinal cortex in episodic memory. Neuron 2001; 26: 1467–1475.

18. van Groen T, Miettinen P, Kadish I. The entorhinal cortex of the mouse: organization of the subiculo-entorhinal connections. J Neurosci Res 2001; 63: 533–543.

19. Kuliwizicz-Waniewska M, Verkhratsky A, Chvatáal A, Sykova E, Rodriguez JJ. Astrocytic cytoskeletal atrophy in the visual cortex of a triple transgenic mouse model of Alzheimer's disease. J Anat 2012; 221: 252–262.

20. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 498–509.

21. Khachaturian ZS. Calcium, membranes, aging, and Alzheimer’s disease. Introduction and overview. Ann Rev Neurosci 1986; 653: 1–4.

22. Khachaturian ZS. HypothESIS on the regulation of cytosol calcium concentration and the aging brain. Neurobiol Aging 1987; 8: 345–346.

23. Verkhratsky A, Toescu EC. Calcium and neuronal aging. Trends Neurosci 1998; 21: 7–27.

24. Oddo S, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 2010; 285: 12463–12468.

25. Schools GP, Kimeberg HK. mGluR3 and mGluR5 are the predominant metabotrophic glutamate receptor mRNAs expressed in hippocampal astrocytes acutely isolated from young rats. J Neurosci Res 1999; 58: 533–543.

26. Kuliwizicz-Waniewska M, Verkhratsky A, Chvatáal A, Sykova E, Rodriguez JJ. Astrocytic cytoskeletal atrophy in the visual cortex of a triple transgenic mouse model of Alzheimer's disease. J Anat 2012; 221: 252–262.

27. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat Rev Neurosci 2007; 8: 498–509.

28. Khachaturian ZS. Calcium, membranes, aging, and Alzheimer’s disease. Introduction and overview. Ann Rev Neurosci 1986; 653: 1–4.

29. Khachaturian ZS. HypothESIS on the regulation of cytosol calcium concentration and the aging brain. Neurobiol Aging 1987; 8: 345–346.

30. Verkhratsky A, Toescu EC. Calcium and neuronal aging. Trends Neurosci 1998; 21: 7–27.

31. Stutzmann GE. The pathogenesis of Alzheimers disease is it a lifelong ‘calciumopathy’? Neuroscientist 2007; 13: 546–559.

32. Berndt MJ. Calcium hypothesis of Alzheimer’s disease. Pfluegers Arch 2010; 459: 441–449.

33. Green KN, Smith IF, LaFerla FM. Role of calcium in the pathogenesis of Alzheimer’s disease and transgenic models. Sub-Cell Biochem 2007; 45: 507–521.

34. Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 2010; 285: 12463–12468.

35. Supnet C, Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 2010; 47: 183–189.

36. Verkhratsky A, Rodriguez JJ, Parpura V. Calcium signalling in astrogliosis. Molec Cell Endocrinol 2013; 353: 45–56.

37. Niedergaard M, Rodriguez JJ, Verkhratsky A. Glial calcium and diseases of the nervous system. Cell Calcium 2010; 47: 140–149.

38. Stutzmann GE, Mattson MP. Endoplasmic reticulum Ca²⁺ handling in excitable cells in health and disease. Pharmacol Rev 2011; 63: 700–727.

39. Surmeier DJ, Guzman JN, Sanchez-Padilla J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson’s disease. Cell Calcium 2010; 47: 175–182.

40. Szudyilowska K, Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium 2010; 47: 122–129.

41. Toescu EC, Verkhratsky A. The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell 2007; 6: 267–273.

42. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Goldie TE, Kayed R et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβj and synaptic dysfunction. Neurouron 2003; 39: 409–421.

43. Fresu L, Dehpour A, Genazzani AA, Carafoli E, Guerin D. Plasma membrane calcium ATPase isoforms in astrocytes. J Neurosci Res 2001; 63: 533–543.

44. Giuffrida ML, Caraci F, Pignaturo B, Cataldo S, De Bona P, Bruno V et al. Jβ-amyloid monomers are neuroprotective. J Neurosci 2009; 29: 10582–10587.

45. Sai A, Peich V, Wilson NR, Passafaro M, Liu G, Sheng M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron 2001; 31: 115–130.

**Cell Death and Disease** is an open-access journal published by *Nature Publishing Group*. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit [http://creativecommons.org/licenses/by-nc-nd/3.0/](http://creativecommons.org/licenses/by-nc-nd/3.0/)